Abstract
U12, one of 20 derivatives synthesized from ursodeoxycholic acid (UDCA), has been found to have anticancer effects in liver cancer cell lines (SMMC-7721 and HepG2) and to protect normal liver cells from deoxycholic acid (DCA) damage (QSG-7701). Its anticancer mechanism was investigated using computer-aided network pharmacology and comparative proteomics. Results showed that its anti-malignancy activities were activated by mTOR/S6K1, cyclinD1/CDK2/4 and caspase-dependent apoptotic signaling pathways in hepatocellular carcinoma cells (HCC). The action of U12 may be similar to that of rapamycin. Animal testing confirmed that U12 exerted better anti-tumor activity than UDCA and had less severe side effects than fluorouracil (5-Fu). These observations indicate that U12 differs from UDCA and other derivatives and may be a suitable lead for the development of compounds useful in the treatment of HCC.
Highlights
Hepatocellular carcinoma (HCC) accounts for 75–90% of all cases of liver cancer in most countries
Cytotoxicity of ursodeoxycholic acid (UDCA) derivatives to normal and liver cancer cell lines An MTT assay was used to investigate the effects of UDCA and its derivatives on the viability of SMMC-7721, HepG2, and QSG-7701 (Fig. 2A–C)
Considering UDCA can antagonize deoxycholic acid (DCA)-induced impairment to different extents depending on the conditions, whether U12 may prevent the action of DCA was here evaluated [21, 22]
Summary
Hepatocellular carcinoma (HCC) accounts for 75–90% of all cases of liver cancer in most countries. HCC is the sixth most common cancer in the world and it is especially common in Africa, southeast Asia, and China [1]. The majority of cases of HCC arise against a background of chronic liver disease, including hepatitis B virus (HBV) and hepatitis C virus (HCV), or ethanol abuse. U12 and Anti-Hepatoma Drug Lead of HCC is growing in the U.S and some European countries [1, 2]. These factors have intensified research efforts into new treatment strategies, there still are few effective drugs without drug resistance. Sorafenib (previously known as BAY 43-9006) is the only drug approved for the treatment for HCC by the Food and Drug Administration of the United States
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.